JakartaPost-July 8, 2021

Two companies from Indonesia and Singapore have developed saliva-based COVID-19 polymerase chain reaction (PCR) test kits that are said to be more efficient, more comfortable but nearly as accurate as throat or nasal swabs. State-owned pharmaceutical holding company PT Bio Farma recently released a spit sample COVID-19 test kit named Bio Saliva developed in cooperation with genomic technology start-up Nusantics. The kit has a sensitivity rate of 88.89 to 93.57 percent for detecting COVID-19, according to a Bio Farma press release from Saturday, not far below the 95 percent achieved with nasopharyngeal or oropharyngeal swabs, the gold standard for PCR testing. Meanwhile, Singapore-based medical technology company Nalagenetics has developed a saliva-based COVID-19 test kit called QuickSpit. The company claimed that the “concordance” of QuickSpit results was at 97 percent when compared to conventional PCR tests.

Read more athttps://www.thejakartapost.com/paper/2021/07/07/spitting-contest-indonesian-singaporean-firms-offer-saliva-based-covid-19-tests.html.